Neulasta and Pregnancy
In studies on Neulasta and pregnancy, the medication increased the risk of miscarriages and low fetal weight when it was given to pregnant rabbits. However, since animals do not always respond to drugs the same way that humans do, Neulasta can be prescribed to a pregnant woman if the benefits outweigh the possible risks. If you are taking Neulasta and pregnancy occurs, notify your healthcare provider.
Neulasta® (pegfilgrastim) is a medication used to prevent infections in people undergoing chemotherapy. In animal studies that looked at the effects of Neulasta during pregnancy, the drug increased the risk of miscarriages.
The U.S. Food and Drug Administration (FDA) uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Neulasta was given a pregnancy Category C classification because of problems in animal studies. Giving Neulasta to pregnant rabbits increased the risk of miscarriages and low fetal weight. It did not increase the risk of birth defects.
However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category C medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the pregnant woman outweigh any possible risks to the unborn child.
If you are pregnant or thinking of becoming pregnant while taking Neulasta, let your healthcare provider know. He or she will consider the benefits and risks of using the medication during pregnancy before making a recommendation for your particular situation.